AbbVie Inc. (ABBV)
After hours:
| Previous close | 169.54 |
| Open | 168.59 |
| Bid | 164.97 x 800 |
| Ask | 170.53 x 800 |
| Day's range | 166.74 - 169.11 |
| 52-week range | 130.96 - 182.89 |
| Volume | |
| Avg. volume | 5,617,229 |
| Market cap | 300.196B |
| Beta (5Y monthly) | 0.56 |
| PE ratio (TTM) | 61.69 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 6.20 (3.69%) |
| Ex-dividend date | 12 Apr 2024 |
| 1y target est | N/A |
- PR Newswire
Allergan Aesthetics Invites Consumers to Be the Face of BOTOX® Cosmetic (onabotulinumtoxinA) and Their Other Biggest Brands
Allergan Aesthetics, an AbbVie company (NYSE: ABBV), is offering consumers an opportunity to be featured in upcoming campaigns for their biggest brands, including BOTOX® Cosmetic, the JUVÉDERM® Collection of Fillers, and Allē, the Allergan Aesthetics loyalty rewards program. Beginning today, consumers—including existing patients and those who are considering aesthetic treatment—can apply for a chance to be included in future brand campaigns. The first Allergan Aesthetics open casting call for BO
- PR Newswire
Phase 3 SELECT-GCA Study of Upadacitinib (RINVOQ®) Showed Positive Results in Patients With Giant Cell Arteritis
AbbVie (NYSE: ABBV) today announced positive top-line results from SELECT-GCA, a Phase 3, multicenter, randomized, double-blind, placebo-controlled study, showing upadacitinib (RINVOQ®; 15 mg, once daily) in combination with a 26-week steroid taper regimen achieved its primary endpoint of sustained remissiona from week 12 through week 52 in adults with giant cell arteritis (GCA). In this study, 46 percent of patients receiving upadacitinib 15 mg in combination with a 26-week steroid taper regime
- PR Newswire
AbbVie Announces Late-Breaking Data at AAN Supporting Long-Term Safety and Efficacy of Atogepant (QULIPTA®) for Preventive Treatment of Migraine
AbbVie (NYSE: ABBV) today announced an interim analysis of an ongoing Phase 3, open-label 156-week extension study evaluating the long-term safety and tolerability of oral atogepant for the prevention of migraine in participants with chronic or episodic migraine. The overall long-term safety results were consistent with the known safety profile of atogepant in chronic and episodic migraine, and no new safety signals were identified. These results also support improvements in key efficacy outcome
